FIELD: medicine.
SUBSTANCE: catheteris introduced into the urethra. It is directed through the anterior urethra, the external sphincter. Then, through the posterior urethra, passing the posterior sphincter, it is entered into the bladder, where it is bent, thereby introducing the entire length of the catheter. Then, saline solution in a volume of 8-10 ml is injected into the shell cavity from the end of the first catheter layer and thus, the above shell is spread to form a ball, free in the lumen of the urinary bladder. Then the catheter is pulled until resistance appears and thus obturate the internal opening of the urethra. Then, 5 ml of sterile saline solution is injected into the catheter shell cavity, located at the level of the external sphincter, and thus, the specified shell located at the external sphincter is spread as a ball used to hermetically close the distal sphincter of the prostate gland. Then a syringe is used to inject a medicinal mixture under the pressure of the syringe piston through the central tube of the catheter into the prostate. 20 ml of the previously prepared medicinal mixture, prepared as follows: chymopsin or trypsin is diluted in 5 ml of saline, the solution transferred into a sterile graduated test tube or tank with a volume of 25-30 ml, 4 ml of 2% lidocaine, 2 ml of trental (20 mg/ml), 2 ml of dexamethasone (4 mg/ml) and an antibiotic: ceftriaxone - 1.0 gor gentamicin - 2 ml with a concentration of 40 mg/ml, or vidokcin - 0.1 g are added, then the total saline solution is adjusted to 20 ml, is injected into the prostate. Under the pressure of the syringe piston, drugs are injected into the ducts of the prostate gland, then into the acini, thereby impregnating the prostate tissue. Then, 20 minutes after, 2 ml of metrogyl with concentration of 5 mg/ml is introduced and left for another 20-30 minutes in this exposition, and then the catheter is removed emptying the previously disclosed expanding shells, and then 2-4 procedures described above are performed every 3-4 days.
EFFECT: method allows to achieve stable remission, shortened treatment time and absence of side effects from prolonged systemic antibacterial treatment.
2 dwg, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR COMPLEX REHABILITATION TREATMENT OF PATIENTS WITH CHRONIC PROSTATITIS | 2023 |
|
RU2824483C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING PROSTATE DISEASES (VERSIONS) | 2009 |
|
RU2430733C2 |
METHOD OF DIAGNOSIS OF CHRONIC PROSTATITIS | 1999 |
|
RU2140636C1 |
TETRAPEPTIDE REGULATING PROSTATE FUNCTION, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD OF ITS USING | 2001 |
|
RU2177802C1 |
METHOD OF TREATING CHRONIC ABACTERIAL PROSTATITIS | 2012 |
|
RU2479331C1 |
METHOD FOR SURGICAL TREATMENT OF PATIENTS WITH LOCALIZED FORMS OF PROSTATE CANCER AND URETHRAL STRICTURES | 2021 |
|
RU2770733C1 |
METHOD AND DEVICE FOR TREATING THE CASES OF CHRONIC PROSTATITIS | 2000 |
|
RU2195971C2 |
METHOD OF TREATING CHRONIC INFECTIOUS PROSTATITIS | 2000 |
|
RU2195232C2 |
COMBINED METHOD FOR SURGICAL TREATMENT OF PATIENTS WITH LOCALISED FORMS OF PROSTATE CANCER AND STONES IN THE MIDDLE AND LOWER THIRDS OF THE URETER | 2022 |
|
RU2784592C1 |
METHOD OF TREATING CHRONIC ABACTERIAL PROSTATITIS | 2012 |
|
RU2478408C1 |
Authors
Dates
2017-11-28—Published
2016-02-10—Filed